U.S., Feb. 8 -- ClinicalTrials.gov registry received information related to the study (NCT06814964) titled 'RhTNK-tPA Thrombolytic Removal of Intraventricular Hemorrhage' on Feb. 03.
Brief Summary: The purpose of this pilot study is to determine the safety and optimal dose of clot lysis with rhTNK-tPA for intraventricular hemorrhage, using stereotactic guidance for extraventricular drain placement.
Study Start Date: Feb. 01
Study Type: INTERVENTIONAL
Condition:
Intraventricular Hemorrhage
Intervention:
DRUG: Low dose group
The calculated injection amount of tenecteplase (tenecteplase injection amount = volume of intraventricular hematoma x 0.009 mg/ml) was diluted to 1ml with sterile injection water, and administered via the EVD.
D...